

NPI Summary Submission Report by Measure
Report Includes Data from the January 2008 through February 2009 TAP File

Clinical Condition and Measure	# Eligible NPI ^d	NPI Participation per Measure		Participant Reporting Information			# NPI Submitting ≥80% ^g	% Submitting ≥80% ^h
		# NPI Submitting ^e	% Total Eligible NPI Submitting ^f	Reporting Denominator: Eligible Cases ^a	Numerator: Valid QDCs Reported ^b	National Reporting Rate ^c		
Advance Care Plan ⁱ	597,965	4,263	0.71%	N/A	N/A	N/A	1,113	26.11%
#47 Advance Care Plan	597,965	4,263	0.71%	867,861	390,574	45.00%	1,113	26.11%
Arthritis-Osteoarthritis ⁱ	208,326	350	0.17%	N/A	N/A	N/A	85	24.29%
#109 Patients with OA with an Assessment of Pain and Function	208,326	350	0.17%	66,473	32,235	48.49%	85	24.29%
Arthritis-Rheumatoid ⁱ	139,009	386	0.28%	N/A	N/A	N/A	172	44.56%
#108 DMARD Therapy in Rheumatoid Arthritis	139,009	386	0.28%	27,099	17,247	63.64%	172	44.56%
Asthma ⁱ	44,860	307	0.68%	N/A	N/A	N/A	94	30.62%
#53 Pharmacologic Therapy	44,860	290	0.65%	562	404	71.89%	205	70.69%
#64 Asthma Assessment	44,860	164	0.37%	346	247	71.39%	110	67.07%
Breast Cancer ⁱ	510,725	8,241	1.61%	N/A	N/A	N/A	2,223	26.97%
#71 Hormonal Therapy for Stage IC-III ER/PR Positive Breast Cancer	100,809	1,523	1.51%	97,657	48,786	49.96%	344	22.59%
#74 RT Recommended for Invasive Breast Cancer Patients with Breast Conserving Surgery	20,434	726	3.55%	4,947	2,470	49.93%	213	29.34%
#99 Breast Cancer Patients with a pT and pN Category and Histologic Grade	7,478	4,048	54.13%	42,475	29,454	69.34%	1,965	48.54%
#112 Screening Mammography	502,834	2,211	0.44%	119,108	36,945	31.02%	299	13.52%
Bronchitis ⁱ	96,739	65	0.07%	N/A	N/A	N/A	25	38.46%
#116 Inappropriate Antibiotic Treatment for Adults	96,739	65	0.07%	308	143	46.43%	25	38.46%
Coronary Artery Bypass Graft (CABG) ⁱ	4,094	1,277	31.19%	N/A	N/A	N/A	512	40.09%
#43 Use of IMA in CABG Surgery	4,094	1,271	31.05%	37,017	28,149	76.04%	801	63.02%
#44 Preoperative Beta-blocker in Patients with Isolated CABG Surgery	4,094	909	22.20%	26,647	18,828	70.66%	511	56.22%

^a The number of instances for which participating TIN/NPIs were eligible to report the measure (the number of eligible denominator instances found in claims for participating eligible professionals).

^b For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

^c The # of reported instances divided by the eligible cases.

^d The # of unique TIN/NPI combinations meeting denominator criteria for any of the PQRI measures. This includes only valid occurrences of the denominator.

^e The # of eligible TIN/NPIs that submitted at least one valid, qualifying QDC used appropriately for a measure.

^f The # of TIN/NPI submitting divided by the # of NPI eligible.

^g The # of TIN/NPIs who submitted the measure on 80% or greater of eligible instances.

^h The # of TIN/NPI submitting ≥80% divided by the # of NPI submitting.

ⁱ Unduplicated counts of NPIs (i.e. Clinical Condition/Topic and National totals are a unique count of all TIN/NPIs).

Note: The grayed-out cells do not have a calculated national total.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORD).

Clinical Condition and Measure	# Eligible NPI ^d	NPI Participation per Measure		Participant Reporting Information			# NPI Submitting ≥80% ^g	% Submitting ≥80% ^h
		# NPI Submitting ^e	% Total Eligible NPI Submitting ^f	Reporting Denominator: Eligible Cases ^a	Numerator: Valid QDCs Reported ^b	National Reporting Rate ^c		
CAD ⁱ	217,619	12,365	5.68%	N/A	N/A	N/A	994	8.04%
#118 ACE or ARB Therapy for Patients with CAD and Diabetes and/or LVSD	214,952	931	0.43%	145,257	41,160	28.34%	145	15.57%
#6 Oral Antiplatelet Therapy Prescribed for Patients with	217,609	12,206	5.61%	1,401,615	997,541	71.17%	5,960	48.83%
#7 Beta-blocker Therapy for CAD Patients with Prior MI	65,577	5,842	8.91%	158,173	121,359	76.73%	3,074	52.62%
Chemotherapy ^j	6,856	933	13.61%	N/A	N/A	N/A	241	25.83%
#73 Plan Documented Before Chemotherapy Administered	6,856	933	13.61%	15,116	7,947	52.57%	241	25.83%
Chest Pain ^k	63,930	33,832	52.92%	N/A	N/A	N/A	24,125	71.31%
#54 ECG Performed for Non-Traumatic Chest Pain	63,930	33,832	52.92%	1,150,661	911,827	79.24%	24,125	71.31%
Chronic Kidney Disease (CKD) ^l	37,189	477	1.28%	N/A	N/A	N/A	58	12.16%
#120 ACE Inhibitor or ARB Therapy in Patients with CKD	3,572	107	3.00%	1,175	756	64.34%	59	55.14%
#121 Laboratory Testing (Calcium, Phosphorus, iPTH and Lipid Profile)	37,189	205	0.55%	9,600	4,477	46.64%	41	20.00%
#122 Blood Pressure Management	37,189	398	1.07%	41,142	22,913	55.69%	153	38.44%
#123 Plan of Care: Elevated Hemoglobin for Patients	37,189	296	0.80%	27,922	12,458	44.62%	87	29.39%
Colon Cancer ^m	66,959	1,205	1.80%	N/A	N/A	N/A	275	22.82%
#72 Chemotherapy for Stage III	66,959	1,205	1.80%	25,363	12,724	50.17%	275	22.82%
Colorectal Cancer (CRC) ⁿ	557,800	6,320	1.13%	N/A	N/A	N/A	2,680	42.41%
#100 CRC Patients with a pT and pN Category and	7,104	3,877	54.57%	25,504	19,765	77.50%	2,398	61.85%
#113 CRC Screening	550,836	2,443	0.44%	481,928	127,896	26.54%	318	13.02%
Chronic Obstructive Pulmonary Disease (COPD) ^o	206,298	1,964	0.95%	N/A	N/A	N/A	411	20.93%
#51 Spirometry Evaluation	206,298	1,735	0.84%	128,446	75,318	58.64%	659	37.98%
#52 Bronchodilator Therapy	206,298	1,438	0.70%	115,744	67,354	58.19%	465	32.34%
Catheter-Related Bloodstream Infections (CRBSI) ^p	87,628	4,287	4.89%	N/A	N/A	N/A	1,489	34.73%
#76 Prevention of CRBSI - Central Venous Catheter	87,628	4,287	4.89%	91,255	53,141	58.23%	1,489	34.73%

^a The number of instances for which participating TIN/NPIs were eligible to report the measure (the number of eligible denominator instances found in claims for participating eligible professionals).

^b For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

^c The # of reported instances divided by the eligible cases.

^d The # of unique TIN/NPI combinations meeting denominator criteria for any of the PQRI measures. This includes only valid occurrences of the denominator.

^e The # of eligible TIN/NPIs that submitted at least one valid, qualifying QDC used appropriately for a measure.

^f The # of TIN/NPI submitting divided by the # of NPI eligible.

^g The # of TIN/NPIs who submitted the measure on 80% or greater of eligible instances.

^h The # of TIN/NPI submitting ≥80% divided by the # of NPI submitting.

ⁱ Unduplicated counts of NPIs (i.e. Clinical Condition/Topic and National totals are a unique count of all TIN/NPIs).

Note: The grayed-out cells do not have a calculated national total.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORD).

Clinical Condition and Measure	# Eligible NPI ^d	NPI Participation per Measure		Participant Reporting Information			# NPI Submitting ≥80% ^g	% Submitting ≥80% ^h
		# NPI Submitting ^e	% Total Eligible NPI Submitting ^f	Reporting Denominator: Eligible Cases ^a	Numerator: Valid QDCs Reported ^b	National Reporting Rate ^c		
Depression ⁱ	236,952	743	0.31%	N/A	N/A	N/A	223	30.01%
#9 Antidepressant Meds During Acute Phase for Patients with New Episode of MD	236,952	601	0.25%	16,825	8,758	52.05%	211	35.11%
#106 Patients who have MD Disorder who meet DSM IV	99	99	100.00%	3,423	3,423	100.00%	99	100.00%
#107 Patients who have MD Disorder who are Assessed for Suicide Risks	194	194	100.00%	9,865	8,078	81.89%	120	61.86%
Diabetes ⁱ	352,628	28,142	7.98%	N/A	N/A	N/A	91	0.32%
#1 Hemoglobin A1c Poor Control	294,094	18,152	6.17%	617,853	373,819	60.50%	7,898	43.51%
#2 Low Density Lipoprotein Control	294,094	17,429	5.93%	587,121	351,641	59.89%	7,445	42.72%
#3 High Blood Pressure Control	294,094	17,361	5.90%	598,386	364,003	60.83%	7,631	43.95%
#18 Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	43,264	7,106	16.42%	346,026	215,668	62.33%	2,440	34.34%
#19 Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	43,264	5,649	13.06%	269,146	149,690	55.62%	1,786	31.62%
#117 Dilated Eye Exam in Diabetic Patient	318,593	6,578	2.06%	413,550	213,430	51.61%	1,516	23.05%
#119 Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	319,180	2,119	0.66%	87,166	32,777	37.60%	287	13.54%
#126 Diabetic Foot and Ankle Care, Peripheral Neuropathy: Neurological Evaluation	315,776	921	0.29%	66,353	26,406	39.80%	118	12.81%
#127 Diabetic Foot and Ankle Care, Ulcer Prevention: Evaluation of Footwear	315,776	346	0.11%	25,062	9,820	39.18%	51	14.74%
End Stage Renal Disease (ESRD) ⁱ	8,991	836	9.30%	N/A	N/A	N/A	99	11.84%
#78 Vascular Access for Patients Undergoing Hemodialysis	8,877	495	5.58%	68,655	29,279	42.65%	108	21.82%
#79 Influenza Vaccination in Patients with ESRD	8,991	453	5.04%	74,096	26,738	36.09%	58	12.80%
#80 Plan of Care for ESRD Patients with Anemia	8,991	659	7.33%	323,225	186,853	57.81%	222	33.69%
#81 Plan of Care for Inadequate Hemodialysis	8,877	626	7.05%	290,568	158,427	54.52%	205	32.75%
#82 Plan of Care for Inadequate Peritoneal Dialysis	6,652	421	6.33%	10,686	5,582	52.24%	126	29.93%

^a The number of instances for which participating TIN/NPIs were eligible to report the measure (the number of eligible denominator instances found in claims for participating eligible professionals).

^b For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

^c The # of reported instances divided by the eligible cases.

^d The # of unique TIN/NPI combinations meeting denominator criteria for any of the PQRI measures. This includes only valid occurrences of the denominator.

^e The # of eligible TIN/NPIs that submitted at least one valid, qualifying QDC used appropriately for a measure.

^f The # of TIN/NPI submitting divided by the # of NPI eligible.

^g The # of TIN/NPIs who submitted the measure on 80% or greater of eligible instances.

^h The # of TIN/NPI submitting ≥80% divided by the # of NPI submitting.

ⁱ Unduplicated counts of NPIs (i.e. Clinical Condition/Topic and National totals are a unique count of all TIN/NPIs).

Note: The grayed-out cells do not have a calculated national total.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORD).

Clinical Condition and Measure	# Eligible NPI ^d	NPI Participation per Measure		Participant Reporting Information			# NPI Submitting ≥80% ^g	% Submitting ≥80% ^h
		# NPI Submitting ^e	% Total Eligible NPI Submitting ^f	Reporting Denominator: Eligible Cases ^a	Numerator: Valid QDCs Reported ^b	National Reporting Rate ^c		
Falls ⁱ	577,470	8,682	1.50%	N/A	N/A	N/A	3,029	34.89%
#4 Screening for Future Fall Risk	577,470	8,682	1.50%	1,036,175	474,559	45.80%	3,029	34.89%
GERD ⁱ	199,830	750	0.38%	N/A	N/A	N/A	234	31.20%
#77 Assessment of GERD Symptoms in Patients Receiving Chronic Medication for GERD	199,830	750	0.38%	35,924	21,107	58.75%	234	31.20%
Glaucoma ⁱ	45,229	8,749	19.34%	N/A	N/A	N/A	3,619	41.36%
#12 Optic Nerve Evaluation	45,229	8,749	19.34%	1,172,487	791,697	67.52%	3,619	41.36%
Heart Failure ⁱ	204,705	9,450	4.62%	N/A	N/A	N/A	2,767	29.28%
#5 ACE Inhibitor or ARB Therapy for LVSD	204,705	9,224	4.51%	341,271	208,730	61.16%	3,578	38.79%
#8 Beta-blocker Therapy for LVSD	203,042	4,642	2.29%	204,618	129,969	63.52%	2,110	45.45%
Hepatitis C (HCV) ⁱ	61,944	421	0.68%	N/A	N/A	N/A	12	2.85%
#83 Testing of Patients with Chronic HCV for Hepatitis C Viremia	61,944	246	0.40%	2,475	1,355	54.75%	78	31.71%
#84 Initial Hepatitis C RNA Testing	32,237	203	0.63%	2,058	1,446	70.26%	93	45.81%
#85 Genotype Testing Prior to Therapy	32,237	211	0.65%	2,633	1,692	64.26%	90	42.65%
#86 Consideration for Antiviral Therapy	32,237	156	0.48%	1,846	1,145	62.03%	51	32.69%
#87 RNA Testing at Week 12 of Therapy	32,237	92	0.29%	927	412	44.44%	26	28.26%
#88 Hepatitis A and B Vaccination	61,944	204	0.33%	1,918	1,053	54.90%	77	37.75%
#89 Counseling Patients Regarding Use of Alcohol	61,944	167	0.27%	1,419	673	47.43%	49	29.34%
#90 Counseling Patients Regarding Use of Contraception Prior to Starting Antiviral Therapy	23,283	39	0.17%	263	154	58.56%	16	41.03%
HIT ⁱ	733,044	11,021	1.50%	N/A	N/A	N/A	353	3.20%
#124 HIT - Adoption/Use of EHRs	733,044	8,765	1.20%	4,732,891	2,257,343	47.69%	2,790	31.83%
#125 HIT - Adoption/Use of e-Prescribing	644,551	3,826	0.59%	3,331,753	408,635	12.26%	241	6.30%
Imaging-Stroke ⁱ	53,145	7,973	15.00%	N/A	N/A	N/A	2,357	29.56%
#10 CT or MRI Reports	34,179	7,327	21.44%	376,210	212,781	56.56%	2,239	30.56%
#11 Carotid Imaging Reports	41,888	5,316	12.69%	87,446	54,072	61.83%	2,066	38.86%
Influenza ⁱ	620,399	3,223	0.52%	N/A	N/A	N/A	9	0.28%
#110 Vaccination for Patients ≥ 50 Years Old	542,024	3,106	0.57%	742,999	179,500	24.16%	219	7.05%
#129 Universal Vaccine Screening and Counseling	601,395	334	0.06%	119,015	38,155	32.06%	28	8.38%

^a The number of instances for which participating TIN/NPIs were eligible to report the measure (the number of eligible denominator instances found in claims for participating eligible professionals).

^b For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

^c The # of reported instances divided by the eligible cases.

^d The # of unique TIN/NPI combinations meeting denominator criteria for any of the PQRI measures. This includes only valid occurrences of the denominator.

^e The # of eligible TIN/NPIs that submitted at least one valid, qualifying QDC used appropriately for a measure.

^f The # of TIN/NPI submitting divided by the # of NPI eligible.

^g The # of TIN/NPIs who submitted the measure on 80% or greater of eligible instances.

^h The # of TIN/NPI submitting ≥80% divided by the # of NPI submitting.

ⁱ Unduplicated counts of NPIs (i.e. Clinical Condition/Topic and National totals are a unique count of all TIN/NPIs).

Note: The grayed-out cells do not have a calculated national total.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORD).

Clinical Condition and Measure	# Eligible NPI ^d	NPI Participation per Measure		Participant Reporting Information			# NPI Submitting ≥80% ^g	% Submitting ≥80% ^h
		# NPI Submitting ^e	% Total Eligible NPI Submitting ^f	Reporting Denominator: Eligible Cases ^a	Numerator: Valid QDCs Reported ^b	National Reporting Rate ^c		
Leukemia (CLL) ⁱ	32,485	1,387	4.27%	N/A	N/A	N/A	577	41.60%
#70 Baseline Flow Cytometry	32,485	1,387	4.27%	16,599	10,515	63.35%	577	41.60%
Macular Degeneration ⁱ	68,163	8,755	12.84%	N/A	N/A	N/A	3,205	36.61%
#14 Dilated Macular Examination	68,163	8,755	12.84%	1,017,607	667,509	65.60%	3,205	36.61%
Myelodysplastic Syndrome (MDS) and Acute Leukemias ⁱ	24,472	1,271	5.19%	N/A	N/A	N/A	182	14.32%
#67 Baseline Cytogenetic Testing Performed on Bone Marrow	24,472	1,029	4.20%	18,891	10,880	57.59%	299	29.06%
#68 Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	19,502	870	4.46%	16,476	8,916	54.12%	229	26.32%
Medication Management ⁱ	622,161	3,624	0.58%	N/A	N/A	N/A	761	21.00%
#46 Medication Reconciliation	428,420	1,964	0.46%	70,700	22,250	31.47%	362	18.43%
#130 Documentation of Current Medications	264,820	1,675	0.63%	97,105	44,836	46.17%	454	27.10%
Mental Health ⁱ	96,692	326	0.34%	N/A	N/A	N/A	33	10.12%
#133 Screening for Cognitive Impairment	56,703	264	0.47%	10,978	7,659	69.77%	153	57.95%
#134 Screening for Clinical Depression	96,484	150	0.16%	8,939	4,323	48.36%	38	25.33%
Myeloma ⁱ	31,644	1,534	4.85%	N/A	N/A	N/A	608	39.63%
#69 Treatment with Bisphosphonates	31,644	1,534	4.85%	13,220	7,949	60.13%	608	39.63%
Myocardial Infarction ⁱ	29,996	13,451	44.84%	N/A	N/A	N/A	10,055	74.75%
#28 Aspirin at Arrival	29,996	13,451	44.84%	55,434	44,500	80.28%	10,055	74.75%
Obesity ⁱ	730,969	1,680	0.23%	N/A	N/A	N/A	275	16.37%
#128 Universal Weight Screening and Follow-Up	730,969	1,680	0.23%	380,102	84,516	22.24%	275	16.37%
Osteoporosis ⁱ	520,050	6,861	1.32%	N/A	N/A	N/A	806	11.75%
#24 Communication with the Physician Managing Ongoing Care Post-Fracture	111,531	776	0.70%	18,692	7,301	39.06%	193	24.87%
#39 Screening or Therapy for Women Aged 65 Years and Older	508,509	4,122	0.81%	527,805	208,225	39.45%	1,031	25.01%
#40 Management Following Fracture	111,531	1,079	0.97%	14,550	4,947	34.00%	350	32.44%
#41 Pharmacologic Therapy	178,693	3,244	1.82%	119,046	61,214	51.42%	984	30.33%

^a The number of instances for which participating TIN/NPIs were eligible to report the measure (the number of eligible denominator instances found in claims for participating eligible professionals).

^b For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

^c The # of reported instances divided by the eligible cases.

^d The # of unique TIN/NPI combinations meeting denominator criteria for any of the PQRI measures. This includes only valid occurrences of the denominator.

^e The # of eligible TIN/NPIs that submitted at least one valid, qualifying QDC used appropriately for a measure.

^f The # of TIN/NPI submitting divided by the # of NPI eligible.

^g The # of TIN/NPIs who submitted the measure on 80% or greater of eligible instances.

^h The # of TIN/NPI submitting ≥80% divided by the # of NPI submitting.

ⁱ Unduplicated counts of NPIs (i.e. Clinical Condition/Topic and National totals are a unique count of all TIN/NPIs).

Note: The grayed-out cells do not have a calculated national total.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORD).)

Clinical Condition and Measure	# Eligible NPI ^d	NPI Participation per Measure		Participant Reporting Information			# NPI Submitting ≥80% ^g	% Submitting ≥80% ^h
		# NPI Submitting ^e	% Total Eligible NPI Submitting ^f	Reporting Denominator: Eligible Cases ^a	Numerator: Valid QDCs Reported ^b	National Reporting Rate ^c		
Otitis ⁱ	84,648	155	0.18%	N/A	N/A	N/A	17	10.97%
#91 AOE: Topical Therapy	84,631	143	0.17%	2,785	1,366	49.05%	54	37.76%
#92 AOE: Pain Assessment	84,631	99	0.12%	3,169	1,494	47.14%	24	24.24%
#93 AOE: Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use	84,631	129	0.15%	2,720	1,251	45.99%	40	31.01%
#94 OME: Diagnostic Evaluation – Assessment of	0	0	0.00%	0	0	0.00%	0	0.00%
#95 OME: Hearing Testing	0	0	0.00%	0	0	0.00%	0	0.00%
#96 OME: Antihistamines or Decongestants – Avoidance of Inappropriate Use	0	0	0.00%	0	0	0.00%	0	0.00%
#97 OME: Systemic Antimicrobials – Avoidance of Inappropriate Use	0	0	0.00%	0	0	0.00%	0	0.00%
#98 OME: Systemic Corticosteroids – Avoidance of Inappropriate Use	0	0	0.00%	0	0	0.00%	0	0.00%
Pain Management ⁱ	163,429	3,514	2.15%	N/A	N/A	N/A	1,436	40.87%
#131 Assessment Prior to Initiation of Patient Treatment	163,429	3,514	2.15%	351,646	114,254	32.49%	1,436	40.87%
Perioperative ⁱ	137,083	29,684	21.65%	N/A	N/A	N/A	22,002	74.12%
#20 Timing of Antibiotic Prophylaxis - Ordering Physician	101,451	7,058	6.96%	361,527	233,115	64.48%	3,118	44.18%
#21 Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	90,536	5,317	5.87%	276,267	173,055	62.64%	2,266	42.62%
#22 Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	93,658	4,961	5.30%	213,417	130,633	61.21%	2,103	42.39%
#23 VTE Prophylaxis	77,825	4,223	5.43%	170,530	107,764	63.19%	1,931	45.73%
#30 Timing of Prophylactic Antibiotics - Administering Physician	29,118	23,799	81.73%	1,389,104	1,343,693	96.73%	22,497	94.53%
#45 Discontinuation of Prophylactic Antibiotics	4,857	1,121	23.08%	118,983	80,454	67.62%	597	53.26%

^a The number of instances for which participating TIN/NPIs were eligible to report the measure (the number of eligible denominator instances found in claims for participating eligible professionals).

^b For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

^c The # of reported instances divided by the eligible cases.

^d The # of unique TIN/NPI combinations meeting denominator criteria for any of the PQRI measures. This includes only valid occurrences of the denominator.

^e The # of eligible TIN/NPIs that submitted at least one valid, qualifying QDC used appropriately for a measure.

^f The # of TIN/NPI submitting divided by the # of NPI eligible.

^g The # of TIN/NPIs who submitted the measure on 80% or greater of eligible instances.

^h The # of TIN/NPI submitting ≥80% divided by the # of NPI submitting.

ⁱ Unduplicated counts of NPIs (i.e. Clinical Condition/Topic and National totals are a unique count of all TIN/NPIs).

Note: The grayed-out cells do not have a calculated national total.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORDJ).

Clinical Condition and Measure	# Eligible NPI ^d	NPI Participation per Measure		Participant Reporting Information			# NPI Submitting ≥80% ^g	% Submitting ≥80% ^h
		# NPI Submitting ^e	% Total Eligible NPI Submitting ^f	Reporting Denominator: Eligible Cases ^a	Numerator: Valid QDCs Reported ^b	National Reporting Rate ^c		
Pharyngitis ^l	0	0	0.00%	N/A	N/A	N/A	0	0.00%
#66 Appropriate Testing for Children	0	0	0.00%	0	0	0.00%	0	0.00%
Plan of Care ^l	142,221	3,221	2.26%	N/A	N/A	N/A	1,211	37.60%
#132 Patient Co-Development of Treatment Plan	142,221	3,221	2.26%	148,910	93,364	62.70%	1,211	37.60%
Pneumonia ^l	238,823	34,401	14.40%	N/A	N/A	N/A	13,313	38.70%
#56 Vital Signs for Community-Acquired Bacterial Pneumonia	196,712	28,313	14.39%	493,078	397,245	80.56%	20,526	72.50%
#57 Assessment of Oxygen Saturation for Community-Acquired Bacterial Pneumonia	196,712	32,261	16.40%	539,011	452,941	84.03%	25,195	78.10%
#58 Assessment of Mental Status for Community-Acquired Bacterial Pneumonia	196,712	28,206	14.34%	471,015	384,860	81.71%	21,463	76.09%
#59 Empiric Antibiotic for Community-Acquired Bacterial Pneumonia	196,712	19,665	10.00%	332,546	260,275	78.27%	14,140	71.90%
#75 Prevention of Ventilator-Associated Pneumonia - Head Elevation	74,680	112	0.15%	7,322	3,687	50.36%	35	31.25%
Pneumonia Pneumococcal ^l	554,687	3,477	0.63%	N/A	N/A	N/A	516	14.84%
#111 Vaccination for Patients 65 years and Older	554,687	3,477	0.63%	792,401	247,154	31.19%	516	14.84%
Prostate Cancer ^l	8,761	681	7.77%	N/A	N/A	N/A	58	8.52%
#101 Appropriate Initial Evaluation of Patients with Prostate Cancer	8,673	431	4.97%	7,899	4,247	53.77%	137	31.79%
#102 Inappropriate Use of Bone Scan for Staging Low-Risk Prostate Cancer Patients	8,673	218	2.51%	35,732	18,426	51.57%	72	33.03%
#103 Review of Treatment Options in Patients with Clinically Localized Prostate Cancer	7,666	372	4.85%	6,724	3,132	46.58%	106	28.49%
#104 Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	4,426	189	4.27%	6,083	2,274	37.38%	16	8.47%
#105 Three-dimensional Radiotherapy for Patients with Prostate Cancer	4,355	422	9.69%	97,630	59,154	60.59%	132	31.28%

^a The number of instances for which participating TIN/NPIs were eligible to report the measure (the number of eligible denominator instances found in claims for participating eligible professionals).

^b For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

^c The # of reported instances divided by the eligible cases.

^d The # of unique TIN/NPI combinations meeting denominator criteria for any of the PQRI measures. This includes only valid occurrences of the denominator.

^e The # of eligible TIN/NPIs that submitted at least one valid, qualifying QDC used appropriately for a measure.

^f The # of TIN/NPI submitting divided by the # of NPI eligible.

^g The # of TIN/NPIs who submitted the measure on 80% or greater of eligible instances.

^h The # of TIN/NPI submitting ≥80% divided by the # of NPI submitting.

^l Unduplicated counts of NPIs (i.e. Clinical Condition/Topic and National totals are a unique count of all TIN/NPIs).

Note: The grayed-out cells do not have a calculated national total.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORD).

Clinical Condition and Measure	# Eligible NPI ^d	NPI Participation per Measure		Participant Reporting Information			# NPI Submitting ≥80% ^g	% Submitting ≥80% ^h
		# NPI Submitting ^e	% Total Eligible NPI Submitting ^f	Reporting Denominator: Eligible Cases ^a	Numerator: Valid QDCs Reported ^b	National Reporting Rate ^c		
Stroke and Stroke Rehabilitation ^l	122,398	3,493	2.85%	N/A	N/A	N/A	299	8.56%
#31 DVT Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	90,664	1,064	1.17%	13,112	7,097	54.13%	425	39.94%
#32 Discharged on Antiplatelet Therapy	90,575	2,316	2.56%	25,066	13,677	54.56%	921	39.77%
#33 Anticoagulant Therapy Prescribed for Afib at Discharge	23,969	587	2.45%	1,601	1,049	65.52%	336	57.24%
#34 t-PA Considered	78,595	1,145	1.46%	10,231	5,951	58.17%	667	58.25%
#35 Screening for Dysphagia	70,298	768	1.09%	10,122	5,476	54.10%	284	36.98%
#36 Consideration of Rehabilitation Services	67,422	1,328	1.97%	13,901	7,368	53.00%	537	40.44%
Syncope ^l	50,448	28,450	56.39%	N/A	N/A	N/A	21,565	75.80%
#55 ECG Performed for Syncope	50,448	28,450	56.39%	343,830	283,102	82.34%	21,565	75.80%
Tobacco Use ^l	566,538	6,078	1.07%	N/A	N/A	N/A	534	8.79%
#114 Inquiry Regarding Tobacco Use	537,505	5,550	1.03%	1,302,758	515,482	39.57%	1,297	23.37%
#115 Advising Smokers to Quit	566,538	4,133	0.73%	1,088,881	328,132	30.13%	532	12.87%
Upper Respiratory Infection (URI) ^l	0	0	0.00%	N/A	N/A	N/A	0	0.00%
#65 Appropriate Treatment for Children	0	0	0.00%	0	0	0.00%	0	0.00%
Urinary Incontinence (UI) ^l	508,705	3,532	0.69%	N/A	N/A	N/A	485	13.73%
#48 Assessment of Presence or Absence of UI in Women Aged 65 Years and Older	508,509	3,289	0.65%	394,278	123,776	31.39%	579	17.60%
#49 Characterization of UI in Women Aged 65 Years and Older	119,044	1,439	1.21%	54,597	31,910	58.45%	449	31.20%
#50 Plan of Care for UI in Women Aged 65 Years and Older	119,044	1,381	1.16%	51,765	30,704	59.31%	460	33.31%
National Total^l	961,970	144,457	0.00%	N/A	N/A	N/A	95,467	0.00%

^a The number of instances for which participating TIN/NPIs were eligible to report the measure (the number of eligible denominator instances found in claims for participating eligible professionals).

^b For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

^c The # of reported instances divided by the eligible cases.

^d The # of unique TIN/NPI combinations meeting denominator criteria for any of the PQRI measures. This includes only valid occurrences of the denominator.

^e The # of eligible TIN/NPIs that submitted at least one valid, qualifying QDC used appropriately for a measure.

^f The # of TIN/NPI submitting divided by the # of NPI eligible.

^g The # of TIN/NPIs who submitted the measure on 80% or greater of eligible instances.

^h The # of TIN/NPI submitting ≥80% divided by the # of NPI submitting.

^l Unduplicated counts of NPIs (i.e. Clinical Condition/Topic and National totals are a unique count of all TIN/NPIs).

Note: The grayed-out cells do not have a calculated national total.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORD).